Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
estradiol + trimegestone
- Development stage
- Phase 4
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Estradiol + trimegestone is a fixed-dose combination of two hormones used primarily in menopausal hormone therapy. Estradiol is a natural estrogen that acts as an agonist at estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), alleviating vasomotor symptoms and preventing postmenopausal osteoporosis by regulating gene transcription in target tissues[3][4][5]. Trimegestone is a potent synthetic progestin (19-norpregnane derivative) with high affinity for the progesterone receptor and minimal activity at androgenic, glucocorticoid, or mineralocorticoid receptors[1][2]. In this combination, estradiol provides estrogenic effects while trimegestone counteracts the risk of endometrial hyperplasia associated with unopposed estrogen therapy. The product is indicated for the treatment of climacteric (menopausal) symptoms and prevention of post-menopausal bone loss[4][5].
- Brand names
- GinotexLovelleMinique
- Other names
- estradiol + trimegestone17-beta-estradiol + trimegestone
02
Targets
ESR1 (ERα)ESR2 (ERβ)GPER1 (G protein-coupled estrogen receptor 1)PR (Progesterone receptor)
Beyond the preview
Go deeper on estradiol + trimegestone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on estradiol + trimegestone.